izvor podataka: crosbi
✓
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it? (CROSBI ID 309040)
Prilog u časopisu | Pismo uredniku | međunarodna recenzija
Trkulja, Vladimir
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it? // British journal of clinical pharmacology, 88 (2022), 7; 3539-3541. doi: 10.1111/bcp.15283
Podaci o odgovornosti
Trkulja, Vladimir
engleski
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?
Meta-analysis of tocilizumab trials to assess effect on mortality - and suggested GRADE level.
COVID-19 ; tocilizumab ; mortality
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
88 (7)
2022.
3539-3541
objavljeno
0306-5251
1365-2125
10.1111/bcp.15283
Povezanost rada
Povezane osobe
Povezane ustanove
Kliničke medicinske znanosti
Poveznice
Indeksiranost
